Differential MHC class II component expression in HPV‐positive cervical cancer cells: Implication for immune surveillance

Effective eradication of human papillomavirus (HPV)‐positive tumors may require CD8+ and CD4+ T‐cell‐mediated immune responses. Ectopic expression of MHC class II surface molecules has been described in the context of cervical cancer, but coexpression with other components of the MHC class II antigen presentation pathway has not been addressed. We have evaluated the MHC class II antigen presentation pathway in malignant squamous epithelium of HPV+ cervical cancer lesions by in situ costaining HLA‐DR with CLIP or DMA/DMB. Cervical cancer cells exhibit 3 MHC class II phenotypes: (i) DR+/CLIP+ or DM+; (ii) DR+/CLIP‐ or DM‐; and (iii) DR‐/CLIP+ or DM+. The identical profile has been identified in HPV+ ME180 cells, which serve as a target for HLA‐DR4‐restricted and HPV68, E7‐specific CD4+ T cells. IFN‐γ pretreatment of ME180 cells, associated with differential trafficking of MHC class II molecules, is necessary for effective T‐cell recognition. Although proinflammatory cytokines may facilitate MHC class II‐restricted antigen recognition in tumor cells, different phenotypes of the MHC class II antigen presentation pathway may be associated with evasion from CD4+‐mediated cellular immune responses. © 2005 Wiley‐Liss, Inc.

[1]  M. Toyota,et al.  Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-γ-induced HLA-DR expression in colorectal and gastric cancer cells , 2004, Oncogene.

[2]  G. Hämmerling,et al.  Mini‐review: Overcoming tumor‐intrinsic resistance to immune effector function , 2004, European journal of immunology.

[3]  M. Klemsz,et al.  Cutting Edge: Induction of the Antigen-Processing Enzyme IFN-γ-Inducible Lysosomal Thiol Reductase in Melanoma Cells Is STAT1-Dependent but CIITA-Independent1 , 2004, The Journal of Immunology.

[4]  F. Koning,et al.  Dissection of the HLA-DR4 Peptide Repertoire in Endocrine Epithelial Cells: Strong Influence of Invariant Chain and HLA-DM Expression on the Nature of Ligands1 , 2004, The Journal of Immunology.

[5]  R. Gutzmer,et al.  A Tumor-Associated Glycoprotein That Blocks MHC Class II-Dependent Antigen Presentation by Dendritic Cells1 , 2004, The Journal of Immunology.

[6]  G. Jakiel,et al.  Alterations in the expression of selected MHC antigens in premalignant lesions and squamous carcinomas of the uterine cervix , 2003, Acta obstetricia et gynecologica Scandinavica.

[7]  E. Unanue,et al.  Cutting Edge: H-2DM Is Responsible for the Large Differences in Presentation Among Peptides Selected by I-Ak During Antigen Processing 1 , 2003, The Journal of Immunology.

[8]  J. Elliott,et al.  Editing of an Immunodominant Epitope of Glutamate Decarboxylase by HLA-DM1 , 2003, The Journal of Immunology.

[9]  Soldano Ferrone,et al.  Tumors as elusive targets of T-cell-based active immunotherapy. , 2003, Trends in immunology.

[10]  Ed Schuuring,et al.  Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma , 2003, Immunogenetics.

[11]  L. Eisenlohr,et al.  Presentation by Recycling MHC Class II Molecules of an Influenza Hemagglutinin-Derived Epitope That Is Revealed in the Early Endosome by Acidification1 , 2003, The Journal of Immunology.

[12]  S. Ferrone,et al.  HLA class I antigen loss, tumor immune escape and immune selection. , 2002, Vaccine.

[13]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[14]  J. Kim,et al.  Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers , 2001, Experimental & Molecular Medicine.

[15]  T. Reichert,et al.  H2-Mβ1 and H2-Mβ2 Heterodimers Equally Promote CLIP Removal in I-Aq Molecules from Autoimmune-prone DBA/1 Mice* , 2001, The Journal of Biological Chemistry.

[16]  E. Schmitt,et al.  MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? , 2000, British Journal of Cancer.

[17]  E. Schmitt,et al.  H2-M, a facilitator of MHC class II peptide loading, and its negative modulator H2-O are differentially expressed in response to proinflammatory cytokines , 2000, Immunogenetics.

[18]  H. Pilch,et al.  Human Papillomavirus Type 33 E7 Peptides Presented by HLA-DR*0402 to Tumor-Infiltrating T Cells in Cervical Cancer , 2000, Journal of Virology.

[19]  P. Magnusson,et al.  Cervical cancer risk: is there a genetic component? , 2000, Molecular medicine today.

[20]  B. Seliger,et al.  CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. , 1999, Journal of immunology.

[21]  M. Sospedra,et al.  HLA-DM and invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules. , 1999, International immunology.

[22]  L. Eisenlohr,et al.  Antigen processing of two H2-IEd-restricted epitopes is differentially influenced by the structural changes in a viral glycoprotein. , 1998, Journal of immunology.

[23]  I. Mellman,et al.  Developmental Regulation of Invariant Chain Proteolysis Controls MHC Class II Trafficking in Mouse Dendritic Cells , 1998, Cell.

[24]  Eric O Long,et al.  Peptide loading onto recycling HLA‐DR molecules occurs in early endosomes , 1998, European journal of immunology.

[25]  P. Delvenne,et al.  Correlation of T‐helper secretory differentiation and types of antigen‐presenting cells in squamous intraepithelial lesions of the uterine cervix , 1998, The Journal of pathology.

[26]  E. Wilander,et al.  Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. , 1998, Cancer research.

[27]  A. Rudensky,et al.  Major Histocompatibility Complex Class II Compartments in Human and Mouse B Lymphoblasts Represent Conventional Endocytic Compartments , 1997, The Journal of cell biology.

[28]  C. Harding,et al.  Early endosomes and a late endocytic compartment generate different peptide-class II MHC complexes via distinct processing mechanisms. , 1997, Journal of immunology.

[29]  E. Unanue,et al.  Distinct antigen MHC class II complexes generated by separate processing pathways. , 1996, The EMBO journal.

[30]  E. Wilander,et al.  Detection of human papillomavirus in cervical intra-epithelial neoplasia, using in situ hybridization and various polymerase chain reaction techniques , 1996, Virchows Archiv.

[31]  S. Beaudenon,et al.  Two novel genital human papillomavirus (HPV) types, HPV68 and HPV70, related to the potentially oncogenic HPV39 , 1996, Journal of clinical microbiology.

[32]  B. Mach,et al.  A novel antigen-processing-defective phenotype in major histocompatibility complex class II-positive CIITA transfectants is corrected by interferon-gamma , 1995, The Journal of experimental medicine.

[33]  M. Stanley,et al.  Immunological events in regressing genital warts. , 1994, American journal of clinical pathology.

[34]  C. Viret,et al.  Defective lymphokine production by most CD8+ and CD4+ tumor‐specific T cell clones derived from human melanoma‐infiltrating lymphocytes in response to autologous tumor cells in vitro , 1994, European journal of immunology.

[35]  B. Mach,et al.  Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. , 1994, Science.

[36]  Eric O Long,et al.  Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen. , 1994, Journal of immunology.

[37]  M. Stanley,et al.  Analysis of HLA‐DR expression on keratinocytes in cervical neoplasia , 1994, International journal of cancer.

[38]  C. Meijer,et al.  Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas , 1994, The Journal of experimental medicine.

[39]  C. Meijer,et al.  Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. , 1993, British Journal of Cancer.

[40]  Barbara J. Reaves,et al.  Epitope mapping of two isoforms of a trans Golgi network specific integral membrane protein TGN38/41 , 1992, FEBS letters.

[41]  H. Delius,et al.  Characterization of a novel human papillomavirus DNA in the cervical carcinoma cell line ME180 , 1991, Journal of virology.

[42]  T. Reichert,et al.  H2-Mbeta 1 and H2-Mbeta 2 heterodimers equally promote clip removal in I-A(q) molecules from autoimmune-prone DBA/1 mice. , 2001, The Journal of biological chemistry.

[43]  R. Rappuoli,et al.  The small GTP binding protein rab7 is essential for cellular vacuolation induced by Helicobacter pylori cytotoxin , 1997, The EMBO journal.

[44]  G. Hämmerling,et al.  Selection of the MHC Class II-associated peptide repertoire by HLA-DM , 1997, Immunologic research.

[45]  G. Fleuren,et al.  The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. , 1994, American journal of clinical pathology.

[46]  C. Meijer,et al.  HLA expression in pre-invasive cervical neoplasia in relation to human papilloma virus infection. , 1993, European journal of cancer.